Editor's note - Page 2 of 19 - Express Pharma

Decoding the skirmish over revised Schedule M

Will 2024 be a year of regulatory renaissance?

Navigating the shift from low-cost to highest value

Building resilience to regulatory risks

India Pharma Inc in M&A mode once again

NMC generics diktat strengthens call for pharma quality

Proposed new drug law may still have flaws

In search of consistent quality

Exploring synergies and de-risking strategies

Why Mankind Pharma’s IPO could be a milestone